$CYCN
Cyclerion Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127116 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $194.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.241M
YoY Change -41.74%
% of Gross Profit
Research & Development $81.00K
YoY Change -86.03%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.322M
YoY Change -44.92%
Operating Profit -$1.128M
YoY Change -81.25%
Interest Expense $42.00K
YoY Change -61.82%
% of Operating Profit
Other Income/Expense, Net $405.0K
YoY Change 278.5%
Pretax Income -$723.0K
YoY Change -87.77%
Income Tax
% Of Pretax Income
Net Earnings -$723.0K
YoY Change -109.56%
Net Earnings / Revenue -372.68%
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$0.29
COMMON SHARES
Basic Shares Outstanding 2.710M 2.710M
Diluted Shares Outstanding 2.526M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.872M
YoY Change -68.44%
Cash & Equivalents $2.872M
Short-Term Investments
Other Short-Term Assets $11.00K
YoY Change -63.33%
Inventory
Prepaid Expenses $621.0K
Receivables $44.00K
Other Receivables $0.00
Total Short-Term Assets $3.548M
YoY Change -64.03%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.350M
YoY Change -0.93%
Other Assets
YoY Change
Total Long-Term Assets $5.350M
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $3.548M
Total Long-Term Assets $5.350M
Total Assets $8.898M
YoY Change -41.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $304.0K
YoY Change -62.65%
Accrued Expenses $353.0K
YoY Change -74.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $700.0K
YoY Change -70.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $700.0K
Total Long-Term Liabilities $0.00
Total Liabilities $700.0K
YoY Change -69.57%
SHAREHOLDERS EQUITY
Retained Earnings -$268.0M
YoY Change 2.02%
Common Stock $276.2M
YoY Change 0.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.198M
YoY Change
Total Liabilities & Shareholders Equity $8.898M
YoY Change -41.51%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$723.0K
YoY Change -109.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.716M
YoY Change -75.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.716M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -1.716M
YoY Change -149.45%
FREE CASH FLOW
Cash From Operating Activities -$1.716M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001755237
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38787
dei Entity Registrant Name
EntityRegistrantName
CYCLERION THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1895370
dei Entity Address Address Line1
EntityAddressAddressLine1
245 First Street, 18th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
327-8778
dei Security12b Title
Security12bTitle
Common Stock, no par value
dei Trading Symbol
TradingSymbol
CYCN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2710096
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2872000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7571000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
44000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
621000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
442000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
3548000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8024000
CY2024Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
5350000
CY2023Q4 us-gaap Other Long Term Investments
OtherLongTermInvestments
5350000
CY2024Q3 us-gaap Assets
Assets
8898000
CY2023Q4 us-gaap Assets
Assets
13374000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
304000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1198000
CY2024Q3 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
72000
CY2023Q4 cycn Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
90000
CY2024Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
324000
CY2023Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
798000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
700000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2086000
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2710096
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2645096
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2530898
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2474159
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
276220000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
275717000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268022000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264417000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8198000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11288000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8898000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13374000
CY2024Q3 cycn Option To License Revenue
OptionToLicenseRevenue
194000
CY2023Q3 cycn Option To License Revenue
OptionToLicenseRevenue
0
cycn Option To License Revenue
OptionToLicenseRevenue
194000
cycn Option To License Revenue
OptionToLicenseRevenue
0
CY2024Q3 us-gaap Revenues
Revenues
194000
CY2023Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
194000
us-gaap Revenues
Revenues
0
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
580000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
230000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1491000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1241000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2131000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4094000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6361000
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1322000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6015000
us-gaap Operating Expenses
OperatingExpenses
4324000
us-gaap Operating Expenses
OperatingExpenses
11156000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1128000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6015000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4130000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11156000
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
42000
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
107000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
180000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
257000
CY2024Q3 cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
363000
CY2023Q3 cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
0
cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
363000
cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
0
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
405000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
107000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
543000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
257000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-723000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5908000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3587000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-10899000
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13474000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
7330000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-723000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
us-gaap Net Income Loss
NetIncomeLoss
-3587000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.29
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.74
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
5.53
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
3.19
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.29
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.43
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.74
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.84
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.19
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2526000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2435000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2510000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2299000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2526000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2786000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2510000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2299000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-723000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
us-gaap Net Income Loss
NetIncomeLoss
-3587000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-6000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-723000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
7564000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3593000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3567000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10452000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6954000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3925000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4181000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1953000
CY2023Q2 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3047000
CY2023Q2 cycn Stock Issued During Period Value Exercise Of Stock Options Restricted Stock Units And Employee Stock Purchase Plans
StockIssuedDuringPeriodValueExerciseOfStockOptionsRestrictedStockUnitsAndEmployeeStockPurchasePlans
24000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
379000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5150000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
159000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
12873000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11288000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1542000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
181000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9923000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1322000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
8783000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-723000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
8198000
us-gaap Profit Loss
ProfitLoss
-3587000
us-gaap Profit Loss
ProfitLoss
-3569000
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
0
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
15752000
cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
363000
cycn Gain Loss From Settlement Of Account Payable
GainLossFromSettlementOfAccountPayable
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3304000
us-gaap Share Based Compensation
ShareBasedCompensation
503000
us-gaap Share Based Compensation
ShareBasedCompensation
964000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
44000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-96000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
179000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-79000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-140000
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
0
cycn Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-107000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-213000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-531000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2157000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-18000
cycn Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
-1912000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-474000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1217000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4693000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19704000
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
10402000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10402000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5024000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-6000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4699000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4274000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7571000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13382000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2872000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9108000
cycn Non Cash Gain On Disposal Of Discontinued Operations
NonCashGainOnDisposalOfDiscontinuedOperations
0
cycn Non Cash Gain On Disposal Of Discontinued Operations
NonCashGainOnDisposalOfDiscontinuedOperations
5350000
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
CY2019Q4 dei Entity Number Of Employees
EntityNumberOfEmployees
0
CY2023Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
5000000
CY2020Q3 cycn Cash Commission Percentage Of Gross Proceeds Of Sales Of Common Stock
CashCommissionPercentageOfGrossProceedsOfSalesOfCommonStock
0.03
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
3353059000
cycn Common Stock Issued Or Sold Under The Atm Offering
CommonStockIssuedOrSoldUnderTheAtmOffering
0
CY2023Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
8000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2400000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
126000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
18000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
11000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
263000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
685000
CY2024Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
43000
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
102000
CY2024Q3 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
324000
CY2023Q4 cycn Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
798000
CY2024Q2 us-gaap Severance Costs1
SeveranceCosts1
100000
CY2024Q3 us-gaap Severance Costs1
SeveranceCosts1
100000
CY2024Q3 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
0
CY2020Q3 cycn Rentable Square Feet Terminated From Lease Agreement
RentableSquareFeetTerminatedFromLeaseAgreement
15700
CY2024Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Rooms
SubleaseTerminationAgreementEstimatedFairValueOfRooms
1500000
CY2024Q3 cycn Sublease Termination Agreement Estimated Fair Value Of Services
SubleaseTerminationAgreementEstimatedFairValueOfServices
2900000
cycn Prepaid Rooms Balance Related To Other Assets
PrepaidRoomsBalanceRelatedToOtherAssets
1400000
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y10M17D
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
CY2024Q3 cycn Services Expense
ServicesExpense
0
cycn Services Expense
ServicesExpense
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
138000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
159000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
503000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
964000
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-723000
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-5908000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-3587000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-10899000
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
13474000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
7330000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-723000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
7566000
us-gaap Net Income Loss
NetIncomeLoss
-3587000
us-gaap Net Income Loss
NetIncomeLoss
-3569000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2526000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2435000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2510000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2299000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2526000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2786000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2510000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2299000
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.29
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.43
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-4.74
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
5.53
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
3.19
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.29
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.43
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-4.74
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
4.84
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
3.19
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2024Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
873715000
CY2023Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
320107000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
873715000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
671144000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
809000
us-gaap Restructuring Charges
RestructuringCharges
-565000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1074000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
300000
CY2024Q3 cycn Option Fee
OptionFee
150000000
CY2024Q3 cycn Option Additional Fee
OptionAdditionalFee
25000000
CY2024Q3 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
200000
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
200000
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-127116-index-headers.html Edgar Link pending
0000950170-24-127116-index.html Edgar Link pending
0000950170-24-127116.txt Edgar Link pending
0000950170-24-127116-xbrl.zip Edgar Link pending
cycn-20240930.htm Edgar Link pending
cycn-20240930.xsd Edgar Link pending
cycn-ex31_1.htm Edgar Link pending
cycn-ex31_2.htm Edgar Link pending
cycn-ex32_1.htm Edgar Link pending
cycn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
cycn-20240930_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending